eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2021-09-25 9 12 719 721 10.12691/ajmcr-9-12-15 AJMCR202191215 article Kara L Heuvelhorst 1 Tyler Diener 1 Hana Manzoor hana.manzoor@beaumont.org 1 Maher Khadra 1 Faisal Musa 1 Syed K Jafri 1 Departments of Radiology and Hematology-Oncology, Beaumont Hospital Dearborn, 18101 Oakwood Blvd, Dearborn, MI 48124 Objective: Here we present one of the first cases of Janssen (Johnson & Johnson Ad26.COV2.S vaccine-associated cerebral venous sinus thrombosis (CVST) in a male patient, and the presumed first case without associated thrombotic thrombocytopenic syndrome (TTS). Method: Patient was identified as a vaccine-related adverse effect due to the unusual presentation of CVST in a male following COVID-19 vaccination, though without thrombocytopenia. Results: Patient presented with left-sided weakness and transient dysarthria. Imaging revealed extensive CVST. Thorough coagulopathy work-up was negative and platelet levels remained within the normal range. Patient improved with non-heparin anticoagulation. Discussion: As more people worldwide continue to be vaccinated against COVID-19, the incidence of vaccine-related complications can be expected to rise. Multiple cases of CVST have been reported in patients following COVID-19 vaccination with associated TTS, nearly all in women. However, this is not the only presentation. Cerebral venous sinus thrombosis should be a consideration in patients who present with headache or altered mental status after COVID vaccination, despite normal platelet levels. http://pubs.sciepub.com/ajmcr/9/12/15/ajmcr-9-12-15.pdf Cerebral Venous Sinus Thrombosis Vaccine Johnson & Johnson Janssen AstraZeneca Clot COVID-19 FDA CDC anti-PF4 Thrombotic Thrombocytopenic Syndrome Ad26COV2S